<DOC>
	<DOC>NCT00716742</DOC>
	<brief_summary>To investigate the effectiveness of the newer IOP-lowering therapies, as prescribed in normal clinical practice, in larger patient numbers. Patients will be assessed at baseline, at each follow-up visit (follow-up visits are variable as per physician discretion) and at final follow-up visit.</brief_summary>
	<brief_title>Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<criteria>A diagnosis of Primary OpenAngle Glaucoma or Ocular Hypertension newly diagnosed OR presenting with insufficiently controlled IOP on current medication (in the opinion of the treating physician) Patient is having both eyes treated Contraindications per product labelling will apply. Patients with any ophthalmic comorbidity with an influence on visual field deterioration or optic nerve head damage.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>